EGFr, FGFr and PDGFr: Emerging Targets for Anticancer Drug Design
Pages 99-108
Sisir Nandi and Manish C. Bagchi

DOI: http://dx.doi.org/10.6000/1929-2279.2016.05.03.3

Published: 23 August 2016

Abstract: Number of cancer affected individuals are increasing day by each year, 11 million people are diagnosed with cancer out of which 7.6 million people die of this deadly disease which is a very significant figure in worldwide mortality. It has been estimated that there will be 16 million new cancer cases every year by 2020. Despite tremendous chemotherapeutics are given to treat cancer toxicity appears to be the most seminal point which can kill normal body cells along with abnormal cancerous cells. Therefore, researchers have been devoted to discover less toxic new chemotherapeutics which can prevent damage to the normal tissues. Recent advancements in molecular biology of cancer and different pathways involved in malignant transformation of cells clearly demonstrate that one of the important mechanisms for progression of cancer is abnormal signal transduction via tyrosine protein kinase. Tyrosine kinase catalyzes phosphorylation of tyrosine residues in proteins. The phosphorylation of protein residue results into the functions of protein. Tyrosine kinase function in many signal transduction cascades wherein extracellular signal is transmitted through the cell membrane receptors (EGFr/FGFr/PDGFr/C-src) to the nucleus where gene encoding this receptor protein maybe modified by this signal. Mutation of gene may causes abnormal signal transduction and leads to the progression of cancer. Therefore EGFr, FGFr and PDGFr have become the emerging targets for development of promising anticancer leads having lower toxicity. The present review is an attempt in this direction dealing with various aspects of cancer, molecular pharmacology of EGFr, FGFr and PDGFr tyrosine protein kinases which has a direct bearing on the design and development of newer chemotherapeutics.

Keywords: Cancer chemotherapy, EGFr, FGFr and PDGFr as emerging drug targets, Anticancer Drug Design.